The tumor was screened for BRAF fusion (Oncomine FOCUS panel, ThermoFisher Scientific), and mutations in the BRAF or IDH1/2 genes (therascreen RGQ PCR, Qiagen), but no genetic alterations could be found. This evidence concerns the gene BRAF and neoplasm.